The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction

References

• GschwindAFischerOMUllrichAThe discovery of receptor tyrosine kinases: targets for cancer therapyNat Rev Cancer2004436137015122207
   PubMed Web of Science ®Google Scholar
• BaselgaBEpidermal growth factor receptor pathway inhibitorsUpdate Cancer Ther20061299310
   Google Scholar
• CiarielloFTortoraGEGFR Antagonists in Cancer TreatmentN Engl J Med2008358111160117418337605
   PubMed Web of Science ®Google Scholar
• CiarielloFTortoraGA novel approach in the treatment of cancer: targeting the epidermal growth factor receptorClin Cancer Res20017102958297011595683
   PubMed Web of Science ®Google Scholar
• ZhuZTargeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectivesActa Pharmacol Sin20072891476149317723181
   PubMed Web of Science ®Google Scholar
• HarariPMEpidermal growth factor receptor inhibition strategies in oncologyEndocr Relat Cancer200411468970815613446
   PubMed Web of Science ®Google Scholar
• DassonvilleOBozecAFischelJLMilanoGEGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differencesCrit Rev Oncol Hematol2007621536117324578
   PubMed Web of Science ®Google Scholar
• KrisMGNataleRBHerbstRSEfficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialJAMA2003290162149215814570950
   PubMed Web of Science ®Google Scholar
• FukuokaMYanoSGiacconeGMulti-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer(The IDEAL 1 Trial) [corrected]J Clin Oncol200321122237224612748244
   PubMed Web of Science ®Google Scholar
• LiuFLiYYuYFuSLiPCloning of novel tumor metastasis-related genes from the highly metastatic human lung adenocarcinoma cell line Anip973J Genet Genomics200734318919517498616
   PubMedGoogle Scholar
• LiWMuDSongLMolecular mechanism of silymarin-induced apoptosis in a highly metastatic lung cancer cell line anip973Cancer Biother Radiopharm201126331732421711112
   PubMed Web of Science ®Google Scholar
• ChuPMChiouSHSuTLEnhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage responseRadiat Oncol20116721244709
   PubMed Web of Science ®Google Scholar
• CariveauMJStackhouseMCuiXLClofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage responseInt J Radiat Oncol Biol Phys200870121322018037589
   PubMed Web of Science ®Google Scholar
• QuanzMBerthaultNRoulinCSmall-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapyClin Cancer Res20091541308131619190126
   PubMed Web of Science ®Google Scholar
• KimIAShinJHKimIHHistone deacetylase inhibitormediated radiosensitization of human cancer cells: class differences and the potential influence of p53Clin Cancer Res2006123 Pt 194094916467109
   PubMed Web of Science ®Google Scholar
• MaPCJagadeeswaranRJagadeeshSFunctional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancerCancer Res20056541479148815735036
   PubMed Web of Science ®Google Scholar
• LindJSLagerwaardFJSmitEFSenanSPhase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancerInt J Radiat Oncol Biol Phys20097451391139619289264
   PubMed Web of Science ®Google Scholar
• StinchcombeTEBogartJANovel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancerOncologist201217568269322531360
   PubMed Web of Science ®Google Scholar
• MerimskyOChengCKAuJSvon PawelJReckMEfficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancerOncol Rep201228272172722614912
   PubMed Web of Science ®Google Scholar
• MehtaVKRadiotherapy and erlotinib combined: review of the preclinical and clinical evidenceFront Oncol201223122645717
   PubMedGoogle Scholar
• MainesMDBiliverdin reductase: PKC interaction at the cross-talk of MAPK and PI3K signaling pathwaysAntioxid Redox Signal20079122187219517919068
   PubMed Web of Science ®Google Scholar
• AksamitieneEKiyatkinAKholodenkoBNCross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balanceBiochem Soc Trans201240113914622260680
   PubMed Web of Science ®Google Scholar
• MengesCWMcCanceDJConstitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptorOncogene200827202934294018059341
   PubMed Web of Science ®Google Scholar
• JungKHParkBHHongSSProgress in cancer therapy targeting c-Met signaling pathwayArch Pharm Res201235459560422553051
   PubMed Web of Science ®Google Scholar
• De BaccoFLuraghiPMedicoEInduction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancerJ Natl Cancer Inst2011103864566121464397
   PubMedGoogle Scholar
• LiuXYaoWNewtonRCScherlePATargeting the c-MET signaling pathway for cancer therapyExpert Opin Investig Drugs20081779971011
   PubMed Web of Science ®Google Scholar
• SteaBFalseyRKislinKTime and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’)Cancer Lett20032021435114643025
   PubMed Web of Science ®Google Scholar
• AnderssonUJohanssonDBehnam-MotlaghPJohanssonMMalmerBTreatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitroActa Oncol200746795196017917826
   PubMed Web of Science ®Google Scholar
• NandaADias-SantagataDCStubbsHUnusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancerClin Lung Cancer20089528528718824451
   PubMed Web of Science ®Google Scholar